natcopharma.co.in valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Disallow: /wp-admin/ Allow: /wp-includes/ Disallow: /beta/ Disallow: /betatest/ Sitemap: https://www.natcopharma.co.in/sitemap.xml | ||
Meta Tags
| Title | Natco Pharma |
| Description | NATCO Announces Launch of the First Generic Version of Revlimid®(lenalidomide capsules), in the Click here for details on Barinat. Home Our Business About Mission & Heritage Values Management Facilities News & Announcements Innovation Analytical Gene |
| Keywords | Natco, Natco Pharmaceutical, Pharma, Natco Pharma Ltd, API’s, Formulations, Block Busters, Natco Trust, Investors, Domestic Formulations, International Formulations, Generic Oncology, Active Pharmaceutical Ingredients, Glatiramer Acetate, Drug |
Server Information
| WebSite | |
| Host IP | 120.138.8.108 |
| Location | - |
Related Websites
| Site | Rank |
More to Explore
natcopharma.co.in Valuation
|
US$6,321,010
Last updated: 2022-06-25 18:31:57
natcopharma.co.in has Semrush global rank of 1,674,464. natcopharma.co.in has an estimated worth of US$ 6,321,010, based on its estimated Ads revenue. natcopharma.co.in receives approximately 729,348 unique visitors each day. Its web server is located in -, with IP address 120.138.8.108. According to SiteAdvisor, natcopharma.co.in is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$6,321,010 |
| Daily Ads Revenue | US$5,835 |
| Monthly Ads Revenue | US$175,044 |
| Yearly Ads Revenue | US$2,100,521 |
| Daily Unique Visitors | 48,624 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| natcopharma.co.in. | A | 590 | IP: 120.138.8.108 |
| natcopharma.co.in. | NS | 3600 | NS Record: ns02.domaincontrol.com. |
| natcopharma.co.in. | NS | 3600 | NS Record: ns01.domaincontrol.com. |
| natcopharma.co.in. | MX | 3600 | MX Record: 0 natcopharma-co-in.mail.protection.outlook.com. |
| natcopharma.co.in. | TXT | 3600 | TXT Record: _globalsign-domain-verification=jxdhS_klp9ExJy23xOKHCXgUi4dbWLgr9srz4nCwQ5 |
| natcopharma.co.in. | TXT | 3600 | TXT Record: v=spf1 include:spf.mailjet.com include:spf.protection.outlook.com -all |
| natcopharma.co.in. | TXT | 3600 | TXT Record: _globalsign-domain-verification=H6zm9JtZBTay1VNKw4AHLAg6Fmo2Fc0r-PfD2Cjzbr |
HtmlToTextCheckTime:2022-06-25 18:31:57
| Click here for details on Barinat. Home Our Business About Mission & Heritage Values Management Facilities News & Announcements Innovation Analytical Generic Research Intellectual Property New Drug Discovery Opportunities Markets India International Investors Financials financials Subsidiary Accounts Stocks Shareholder Information Shareholding Pattern Investor Service Request Form Investor Presentation Statutory Communications Scheme of Amalgamation Unclaimed Dividend Investors Education Protection Fund (IEPF) Buy back PAPER ADVERTISEMENTS Board Meeting Intimations AGM ANNUAL SECRETARIAL COMPLIANCE CERTIFICATE Annual Reports Corporate Governance & Policies Corporate Governance Certificate IR and Shareholder Contacts QIP 2017 People Meet Our People Careers Responsibility CSR Policy Environment, Health & Safety Attivaram Chemical unit-Mekaguda Chemical Unit-Chennai Certification & Awards Natco Trust Business Responsibility Policies Sustainability Report Contact Locations Contact us |